Shanghai RAAS Blood Products Co Ltd
SZSE:002252
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
6.2
8.47
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Shanghai RAAS Blood Products Co Ltd
Shanghai RAAS Blood Products Co Ltd
Cost of Revenue
Shanghai RAAS Blood Products Co Ltd
Cost of Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
|
Cost of Revenue
-¥5B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
-33%
|
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
|
Akeso Inc
HKEX:9926
|
Cost of Revenue
-¥137.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥27.3B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-57%
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥140.8m
|
CAGR 3-Years
-36%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
Shanghai RAAS Blood Products Co Ltd
Glance View
Shanghai RAAS Blood Products Co., Ltd. is a key player in China's biopharmaceutical landscape, specializing in the production and supply of human blood products and diagnostic reagents. Founded in 1992, the company has grown to become one of the largest blood product manufacturers in the country, serving the increasing demand for high-quality and safe blood-derived therapies. The company’s extensive portfolio includes a range of products such as human albumin, immunoglobulins, and coagulants, which are essential for treating various medical conditions, from trauma care to chronic diseases. With a strong commitment to innovation and quality, RAAS has established robust research and development capabilities, ensuring that it stays at the forefront of advancements in blood product technologies. For investors, Shanghai RAAS represents a compelling opportunity in the rapidly expanding Chinese healthcare market. The company operates in a highly regulated environment, giving it a competitive edge through rigorous quality control and adherence to international standards. Furthermore, as China’s aging population grows and healthcare spending increases, the demand for reliable blood products is expected to rise significantly. RAAS has strategically positioned itself to capture this market growth, supported by a diversified customer base that includes hospitals and medical institutions. With its commitment to sustainability, innovation, and shareholder value, investing in Shanghai RAAS not only aligns with a growing industry but also offers the potential for solid returns as the company continues to expand its footprint in both domestic and international markets.
See Also
What is Shanghai RAAS Blood Products Co Ltd's Cost of Revenue?
Cost of Revenue
-5B
CNY
Based on the financial report for Jun 30, 2024, Shanghai RAAS Blood Products Co Ltd's Cost of Revenue amounts to -5B CNY.
What is Shanghai RAAS Blood Products Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 10Y
-33%
Over the last year, the Cost of Revenue growth was -22%. The average annual Cost of Revenue growth rates for Shanghai RAAS Blood Products Co Ltd have been -54% over the past three years , -46% over the past five years , and -33% over the past ten years .
You don't have any saved screeners yet
